Vacc-derived polio hits Nigeria: WHO "cover up"

14 October 2007

The World Health Organization and the US Centers for Disease Control and Prevention (CDC) have come under attack for delaying the public announcement that, since 2005, 71 children have been infected in Nigeria and Niger with polio as a result of taking an oral vaccine against the disease. The revelation that both agencies knew of the problem over a year ago comes as the polio eradication program is already under pressure, with local Muslim clerics claiming that the WHO campaign is part of a conspiracy to sterilize Islamic children (Marketletters passim).

According to news agency MSNBC, the most recent case of 69 children in Nigeria and two in Niger is not unique. In 2001, 22 children were paralysed in the Dominican Republic and Haiti from vaccine-derived polio virus (VDPV). China, Indonesia, Madagascar and the Philippines have since then experienced similar outbreaks.

The decision by the WHO and the CDC to suppress public knowledge of the Nigerian outbreak has already prompted accusations of cover up and conspiracy there. Olen Kew, a CDC virologist, said: "the people who are against immunization may seize on anything that could strengthen their position." The WHO claimed that, because the outbreak was "operational," it did not need to be discussed outside the agency's scientific committee.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight